pH-sensitive 4-amidopiperidine derivatives, pharmaceutical compositions, preparation methods and applications thereof

By designing pH-sensitive 4-amide piperidine derivatives, the activation of μ opioid receptors in inflammatory pathological regions under low pH conditions is achieved, solving the problem of side effects of opioids in treating pain, and significantly improving the Painful effects and reduce side effects.

CN116535390BActive Publication Date: 2024-11-15WUHAN SILING BIOTECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210086363.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-25
Publication Date
2024-11-15
Estimated Expiration
2042-01-25

AI Technical Summary

Technical Problem

Existing opioid analgesics have central nervous system and gastrointestinal side effects when treating moderate to severe pain, and it is difficult to target inflammatory pathological areas, resulting in addictive, respiratory depression and other problems, and it is impossible to avoid side effects in the physiological environment. The emergence of

Method used

Design a pH-sensitive 4-amide piperidine derivative with selective activation of μ opioid receptors under low pH conditions, targeting inflammatory pathological regions, avoiding activation of opioid receptors in physiological environments, thereby reducing side effects .

Benefits of technology

The compound has pH sensitivity to μ receptor affinity under different pH conditions, significantly improves formalin-induced phase I and phase II pain, exhibits good analgesic activity, and reduces somatic-dependent side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116535390B_ABST
    Figure CN116535390B_ABST
Patent Text Reader

Abstract

The present invention provides a pH-sensitive 4-amide piperidine derivative, a pharmaceutical composition, a preparation method and an application thereof. The pH-sensitive 4-amide piperidine derivative is a compound having the general formula I, a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. The experimental results show that the compound of the general formula I provided by the present invention has pH sensitivity in affinity for μ receptors and has low side effects related to μ receptors. The results of animal experiments show that the compound provided by the present invention can not only significantly improve formalin-induced phase I and phase II pain, but also show good analgesic activity in the acetic acid writhing experiment. Therefore, it has good application prospects in the preparation of drugs for preventing or treating pain. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of organic drug synthesis, and relates to a pH-sensitive 4-amide piperidine derivative, a pharmaceutical composition, a preparation method thereof, and an application thereof. In particular, the present invention relates to a pH-sensitive 4-amide piperidine derivative shown in general formula I, a preparation method thereof, a pharmaceutical composition containing the derivative, and an application thereof in the preparation of a drug for treating pain diseases. Background Art

[0002] The process of birth, aging, illness and death is accompanied by the existence of "pain", so the treatment and management of pain is a world-class public health issue closely related to human life. Although the opioid analgesics currently on the market for moderate to severe pain are very effective in relieving pain, they all have relatively serious central nervous system and gastrointestinal side effects, including: addiction, respiratory depression, nausea, vomiting, constipation, excessive sedation, etc. Therefore, the research and development of painkillers without side effects is very urgent. The current market demand for analgesics has shifted from "stronger analgesic effect" to "moderate analgesic effect and better safety", so analgesics without side effects are also called the "holy grail" in the field of analgesic drug research.

[0003] Current research strategies are all centered around central opioid receptors in non-pathological environments, but a variety of pain symptoms (such as arthritis, neuralgia, and surgery) are driven by peripheral sensory neurons and are mostly accompanied by inflammation and tissue acidification (pH 5-7, physiological pH 7.4). In this case, the peripheral opioid receptors and their signaling pathways in the human body are upregulated, and local acidification amplifies the function of heterotrimeric guanine nucleotide binding protein (G protein) coupled receptors and affects the protonation of ligands, which is a necessary condition for ligand binding and activation of opioid receptors.

[0004] Therefore, the local microenvironment and opioid receptors under pathological conditions have the following three important characteristics: a) the peripheral opioid system has analgesic regulatory effects; b) the local microenvironment in pathological areas of inflammation is characterized by a low pH value; c) the binding of classical μ opioid receptor (MOR) agonists to MOR depends on the ionized nitrogen atom of the piperidine ring in its structure and the ionic bond between it and ASP147.

[0005] Based on the above background, Professor Christoph Stein from Charité Hospital affiliated to Free University of Berlin, Germany, first proposed the hypothesis of "pH-sensitive MOR agonists targeting pathological areas of inflammation" in Science magazine in 2017. He speculated that if an agonist that selectively activates μ opioid receptors only under low pH (pathological) conditions could be designed, it would not produce the side effects generally caused by drugs acting on opioid receptors in the central nervous system or intestines in the physiological environment, such as adnexosis.Figure 1 shown.

[0006] Based on this hypothesis, Stein, Rosas and others creatively introduced highly electronegative fluorine atoms around the nitrogen atom on the basis of the structure of the classic opioid drug fentanyl, thereby lowering the high pKa of fentanyl itself and obtaining a series of pH-sensitive MOR agonists NFEPP, FF3, FF6 and RR-49 (as shown below, pH-sensitive MOR agonists (fluorofentanyl structural derivatives) reported in the literature).

[0007]

[0008] In vitro and in vivo experiments have shown that, unlike fentanyl, NFEPP can selectively activate MOR in inflammatory pathological areas (inflammatory and postoperative pain sites, acidic pH microenvironment), achieving targeted analgesia, while also avoiding side effects such as respiratory depression, sedation, constipation, or addiction. Subsequent studies have also shown that NFEPP also targets pain sites and exerts analgesic effects by activating peripheral opioid receptors in chronic sciatic nerve ligation neuralgia models and acetic acid-induced abdominal pain models.

[0009] Therefore, pH-sensitive MOR agonists can target and activate μ receptors in pathological areas of inflammation, thereby exerting analgesic effects, while having the characteristics of low MOR-related side effects compared with traditional MOR agonists.

[0010] In view of this, it is necessary to design an improved pH-sensitive 4-amide piperidine derivative, a pharmaceutical composition, a preparation method and an application thereof to solve the above problems. Summary of the invention

[0011] In order to overcome the deficiencies of the above-mentioned prior art, the purpose of the present invention is to provide a pH-sensitive 4-amide piperidine derivative, a pharmaceutical composition, a preparation method and an application thereof. The pH-sensitive 4-amide piperidine derivative has a high affinity for μ receptors, and the affinity for μ receptors under different pH conditions is pH-sensitive; and it significantly improves formalin-induced phase I and phase II pain, and also exhibits good analgesic activity in the acetic acid writhing test.

[0012] To achieve the above-mentioned object of the invention, the present invention provides a pH-sensitive 4-amide piperidine derivative, which is a compound shown in Formula I, a pharmaceutically acceptable salt thereof, a cocrystal, a tautomer thereof, a mesomer, a racemate, an enantiomer or a diastereomer thereof:

[0013]

[0014] In the formula, R1 is independently selected from substituted or unsubstituted C 1-4 Alkoxy or C 1-4 Alkylamino, substituted or unsubstituted aromatic, substituted or unsubstituted C 3-10 Heterocyclic substituents, substituted or unsubstituted C 3-10 wherein the substituent is selected from deuterium atoms, amino groups, hydroxyl groups, mercapto groups, cyano groups, sulfonamide groups, carboxyl groups, halogen groups, C 1-4 Alkyl, C 1-4 One or more of the alkoxy groups;

[0015] R2 is a hydrogen atom, a methoxymethylene group, a methoxymethylester group, a methoxyformyl group or a methylthioformyl group;

[0016] R3 is independently selected from substituted or unsubstituted C 1-4 Alkyl, substituted or unsubstituted C 1-4 Alkoxy, substituted or unsubstituted aromatic, substituted or unsubstituted heterocyclic aromatic substituents, substituted or unsubstituted C 3-10 wherein the substituent in R3 is selected from deuterium atoms, amino groups, hydroxyl groups, mercapto groups, cyano groups, sulfonamide groups, carboxyl groups, halogen groups, C 1-4 Alkyl, C 1-4 One or more of the alkoxy groups;

[0017] R4 is independently selected from a hydrogen atom, a deuterium atom, an amino group, a hydroxyl group, a thiol group, a cyano group, a sulfonamide group, a carboxyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heterocyclic aromatic group, a substituted or unsubstituted C 3-10 Cycloalkyl, substituted or unsubstituted C 1-4 Alkyl, substituted or unsubstituted C 1-4 Alkoxy, halogen; wherein the substituent in R4 is selected from deuterium atom, amino, hydroxyl, mercapto, cyano, sulfonamide, carboxyl, halogen, C 1-4 Alkyl, C 1-4 One or more of the alkoxy groups;

[0018] n is 0, 1 or 2;

[0019] X is independently selected from methylene or nitrogen, oxygen, or sulfur heteroatoms;

[0020] Y is independently selected from methylene, carbonyl, thiocarbonyl, substituted or unsubstituted imine or nitrogen atom, oxygen atom, sulfur atom heteroatom; wherein the substituent in Y is selected from deuterium atom, amino, hydroxyl, thiol, cyano, sulfonamide, carboxyl, halogen, C 1-4 Alkyl, C 1-4 One or more alkoxy groups.

[0021] In some embodiments, in Formula I, the unsubstituted C 1-4The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, substituted C 1-4 The alkyl group is selected from methoxymethylene, methylthiomethylene or halogen-substituted C 1-4 The halogen is fluorine, chlorine, bromine or iodine.

[0022] In some embodiments, in Formula I, the unsubstituted aromatic group is selected from phenyl and naphthyl, and the substituted aromatic group is selected from halogen, C1-4 alkyl, C1-4 alkoxy, hydroxyl, cyano, mono- or poly-substituted phenyl or naphthyl; wherein the halogen is fluorine, chlorine, bromine or iodine.

[0023] In some embodiments, in Formula I, the unsubstituted heterocyclic aromatic substituent is furan, thiophene, pyridine or pyrimidine, and the substituted heterocyclic aromatic substituent is selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy, hydroxy, cyano mono- or poly-substituted furan, thiophene, pyridine or pyrimidine; wherein the halogen is fluorine, chlorine, bromine or iodine.

[0024] In some embodiments, in Formula I, the unsubstituted C 3-10 Cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononane, cyclodecane, substituted C 3-10 Cycloalkyl is halogen, C 1-4 Alkyl, C 1-4 Alkoxy, hydroxy, cyano mono- or poly-substituted C 3-10 Cycloalkyl; wherein the halogen is fluorine, chlorine, bromine or iodine.

[0025] In some embodiments, in Formula I, the unsubstituted C 3-10 The heterocyclic substituent is aziridine, azetidinyl, pyrrolyl, piperidinyl, piperazinyl, piperidonyl, azacyclononane, azepanyl, azacyclooctyl, azacyclodecane, indoline, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridinyl, substituted C 3-10 The heterocyclic substituent is halogen, C 1-4 Alkyl, C 1-4 Alkoxy, hydroxy, cyano mono- or poly-substituted C 3-10 Heterocyclic substituent; wherein the halogen is fluorine, chlorine, bromine or iodine.

[0026] In some embodiments, the compound represented by Formula I or a pharmaceutically acceptable salt thereof is selected from the following compounds or a pharmaceutically acceptable salt thereof:

[0027] (1), N-(1-(2-(indolyl-1-yl)-2-oxoethyl)-4-(methoxymethyl)piperidin-4-yl)-N-phenylpropionamide;

[0028] (2,) N-(1-(2-(6,7-dihydrothiophene[3,2-c]pyridin-5(4H)-yl)-2-oxoethyl)-4-(methoxymethyl)piperidin-4-yl)-N-phenylpropanamide;

[0029] (3), N-phenyl-N-(1-(2-phenylacetyl)piperidin-4-yl)propionamide;

[0030] (4), N-(4-(methoxymethyl)-1-(2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0031] (5), N-(4-(methoxymethyl)-1-(2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0032] (6), N-(4-(methoxymethyl)-1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0033] (7), N-(4-(methoxymethyl)-1-(2-oxo-2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0034] (8), N-(1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0035] (9), N-(1-(2-oxo-2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide;

[0036] In some embodiments, in Formula I, the pharmaceutically acceptable salt is a salt containing a pharmaceutically acceptable anion, and the anion salt is hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, oxalate, acetate, propionate, lactate, citrate, tartrate, maleate, fumarate, methanesulfonate, ethanesulfonate, propanesulfonate, gluconate, glucarate, benzoate, p-toluate, benzenesulfonate or p-toluenesulfonate.

[0037] The present invention also provides a method for preparing a compound of formula I, a pharmaceutically acceptable salt thereof, a tautomer, a mesomer, a racemate, an enantiomer or a diastereomer thereof, comprising the following steps: obtaining a compound of formula I by a substitution reaction between a compound of formula IA shown in the following formula and a compound of formula IB;

[0038]

[0039] Wherein, Z is chlorine, bromine, iodine, hydroxyl,

[0040] Alternatively, prepare by the following method:

[0041] The compound of the general formula IC shown in the following formula undergoes a substitution reaction with the compound of the general formula ID to obtain the compound of the general formula I;

[0042]

[0043] Wherein, Z is chlorine, bromine, iodine, hydroxyl,

[0044] The present invention also provides a pharmaceutical composition, comprising an effective therapeutic dose of a compound of formula I or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and the pharmaceutical composition can be used to prepare a drug for the prevention and treatment of pain-related diseases. The pain-related diseases include acute pain, such as acute injury pain of soft tissue and joints, postoperative pain, obstetric pain, acute herpes zoster pain, gout, etc. The pain-related diseases include chronic pain, such as strain or degeneration pain of soft tissue and joints, intervertebral disc-derived pain, neurogenic pain, etc. The pain-related diseases include intractable pain, such as trigeminal neuralgia, postherpetic neuralgia, intractable headache, etc. The pain-related diseases include cancer pain, such as advanced tumor pain, tumor metastasis pain, etc. The pain-related diseases include special pain, such as thromboangiitis, intractable angina pectoris, idiopathic chest and abdominal pain, etc.

[0045] The compound of formula I of the present invention or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt and pharmaceutically acceptable excipients are prepared in a form suitable for administration by any appropriate route, and the active compound is preferably in a unit dose form, or in a form in which the patient can self-administer a single dose. The unit dose of the compound or composition provided by the present invention can be expressed in the form of tablets, capsules, injections, granules, tinctures, lozenges, suppositories, regeneration powders or liquid preparations.

[0046] The dosage of the compound or composition used in the method of use thereof will generally vary with the severity of the pain, the patient's weight and the relative efficacy of the compound. As a general guide, a suitable unit dosage may be 0.01 to 1000 mg.

[0047] The pharmaceutical composition provided by the present invention may contain one or more auxiliary materials in addition to the active compound, and the auxiliary materials are selected from the following components: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99 weight percent of the active compound.

[0048] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, injection or transdermal administration in the form of a drug delivery system such as a patch, such as tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, injections, lyophilized powders, or syrups or tinctures. Oral or injectable compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the following: sweeteners, flavoring agents, coloring agents, pH regulators and preservatives.

[0049] Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Aqueous suspensions may also contain one or more preservatives, for example ethylparaben or n-propylparaben, one or more colorants, one or more flavoring agents and one or more sweetening agents.

[0050] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil and the oil suspension may contain a thickener. The above-mentioned sweeteners and flavoring agents may be added.

[0051] The pharmaceutical composition can be in the form of a sterile injection aqueous solution. Acceptable solvents or solvents that can be used include water, Ringer's solution and isotonic sodium chloride solution. The sterile injection can be a sterile injection oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin, and then the oil solution is added to a mixture of water and glycerol to form a microemulsion. The injection or microemulsion can be injected into the patient's blood by local injection. Alternatively, the solution and microemulsion can be given in a manner that can maintain a constant circulating concentration of the compound provided by the present invention. To maintain this constant concentration, a continuous intravenous drug delivery device can be used.

[0052] The pharmaceutical composition can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents as described above. Sterile injection preparations can also be sterile injection solutions or suspensions prepared in parenteral acceptable five-toxic diluents or solvents. In addition, sterile fixed oils can be used as solvents or suspension media.

[0053] The pharmaceutical compositions disclosed herein can be in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a non-irritating excipient that is solid at ordinary temperatures but liquid in the rectum. Such excipients can include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various degrees of polymerization, and mixtures of fatty esters of polyethylene glycol.

[0054] As is well known to those skilled in the art, the dosage of a drug depends on many factors, including but not limited to the following factors: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, etc.; in addition, the best treatment method such as the mode of treatment, the daily dosage of the general formula compound I or the type of salt to be used can be verified according to traditional treatment plans.

[0055] The compounds provided herein may also include isotopic derivatives thereof. The term "isotopic derivative" refers to a compound whose structure differs only in the presence of one or more isotopically enriched atoms. For example, a compound having a structure disclosed herein, except that hydrogen is replaced by "deuterium" or "tritium", or by 18 F-Fluorine ( 18 F isotope) instead of fluorine, or with 11 C-, 13 C-, or 14 C-enriched carbon ( 11 C-, 13 C-, or 14 C-carbon labeling; 11 C-, 13 C-, or 14 Compounds in which a carbon atom is replaced by a C-isotope) are within the scope of the present disclosure. Such compounds can be used, for example, as analytical tools or probes in biological assays, or as in vivo diagnostic imaging tracers for diseases, or as tracers for pharmacodynamics, pharmacokinetics or receptor studies. Deuterated compounds can generally retain activity comparable to that of undeuterated compounds, and when deuterated at certain specific sites, better metabolic stability can be achieved, thereby obtaining certain therapeutic advantages (such as increased half-life in vivo or reduced dosage requirements).

[0056] The compounds provided by the present invention also include various deuterated forms of compounds of formula I. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds of formula I with reference to relevant literature. Commercially available deuterated starting materials can be used when preparing deuterated forms of compounds of formula I, or they can be synthesized using deuterated reagents using conventional techniques, and deuterated reagents include but are not limited to deuterated borane, trideuterated borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.

[0057] With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to a sufficient amount of the drug or agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the subject, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0058] The beneficial effects of the present invention are:

[0059] 1. The pH-sensitive 4-amide piperidine derivatives provided by the present invention are shown by in vitro isotope receptor ligand binding tests that the compounds of general formula I provided by the present invention have a high affinity for μ receptors, and the affinity for μ receptors under different pH conditions is pH-sensitive. At the same time, animal test results also show that the compounds of the present invention can not only significantly improve formalin-induced phase I and phase II pain, but also show good analgesic activity in acetic acid writhing experiments. Since these in vitro action targets and in vivo pharmacological models are closely related to pain, the compounds provided by the present invention have the potential to prepare drugs for treating pain-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 It is a pH-sensitive MOR agonist that targets pathological areas of inflammation.

[0061] Figure 2 Schematic diagram of the results of the acetic acid writhing test on mice for the preferred compound 6.

[0062] Figure 3 Schematic diagram of the experimental results of the rat formalin-induced pain model of the preferred compound 6.

[0063] Figure 4 Schematic diagram of the results of the naloxone withdrawal experiment in mice with the preferred compound 6. DETAILED DESCRIPTION

[0064] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is described in detail below in conjunction with specific embodiments.

[0065] It should also be noted that, in order to avoid obscuring the present invention due to unnecessary details, only structures and / or processing steps closely related to the scheme of the present invention are shown in the specific embodiments, while other details that are not closely related to the present invention are omitted.

[0066] In addition, it should be noted that the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.

[0067] Test method:

[0068] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR measurements were performed using a Bruker AV-500 nuclear magnetic spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3) and deuterated methanol (CD3OD) as the measuring solvents, and tetramethylsilane (TMS) as the internal standard. The chemical shift (δ) unit is ppm.

[0069] Aglient 1260-1956A Quadrupole (manufacturer: Aglient, MS model: 1956A Quadrupole) was used for MS measurement; Aglient LC-MS / MS QTOF 6530 (manufacturer: Aglient, MS model: QTOF 6530) was used for HR-MS measurement.

[0070] The following examples are for illustrative purposes only and are not intended to limit the present invention.

[0071] All temperatures are in degrees Celsius (°C).

[0072] A. Compound Synthesis Examples

[0073] Example 1

[0074] N-(1-(2-(Indolin-1-yl)-2-oxoethyl)-4-(methoxymethyl)piperidin-4-yl)-N-phenylpropanamide (1)

[0075] Reaction:

[0076]

[0077] 2-Chloro-1-(indolin-1-yl)ethane-1-one (1a) is synthesized by the reaction of 2,3-dihydro-1H-indole with 2-chloroacetyl chloride. The intermediate 1a is further reacted with 4-(methoxymethyl)-N-phenylpiperidin-4-amine (1b) to generate intermediate 1c, which is finally reacted with propionyl chloride to obtain the target product (1).

[0078] S1. Synthesis of 2-chloro-1-(indolyl-1-yl)ethan-1-one (1a)

[0079] Take 3.3g of 2-chloroacetyl chloride and dissolve it in 20mL of dichloromethane, cool it to 0-5℃ in an ice bath, add 2,3-dihydro-1H-indole dissolved in 10mL of dichloromethane dropwise, add 5.6g of potassium carbonate, and continue to react for 6h. After the reaction is completed, add 30mL of purified water, separate the dichloromethane layer with a separatory funnel, extract the water layer with dichloromethane twice (20mL*2), combine the dichloromethane layers, wash them with saturated brine in turn, dry them with anhydrous magnesium sulfate, and remove the solvent by distillation under reduced pressure to obtain 4.4g of white solid with a yield of 83.7%.

[0080] S2. Synthesis of 1-(indolin-1-yl)-2-(4-(methoxymethyl)-4-(anilino)piperidin-1-yl)ethan-1-one (1c)

[0081] Take 0.7 g of the reaction product of step S1 and 0.6 g of 4-(methoxymethyl)-N-phenylpiperidin-4-amine (1b), dissolve them in 20 mL of acetonitrile, continue to add 0.8 g of triethylamine and 0.04 g of potassium iodide, heat to 65°C and stir to react for 8 h. After the reaction is completed, remove the solvent by rotary evaporation to obtain 1.2 g of yellow oil, and obtain 0.8 g of light yellow solid by silica gel column chromatography (200-300 mesh silica gel, dichloromethane: methanol = 25: 1), with a yield of 82.7%.

[0082] S3, N-(1-(2-(indolyl-1-yl)-2-oxoethyl)-4-(methoxymethyl)piperidin-4-yl)-N-phenylpropionamide (1)

[0083] Take 0.7g of the reaction product of step S2 and 0.6g of propionyl chloride, dissolve in 25mL of dichloromethane, react at room temperature for 1h, add 0.7g of triethylamine, and continue to react for 6h. After the reaction is completed, add 25mL of purified aqueous solution, stir for 5min, and separate the dichloromethane layer with a separatory funnel. Extract the water layer twice with dichloromethane and combine the dichloromethane layers, wash with saturated brine, dry over anhydrous sodium sulfate, and remove the solvent by rotary evaporation to obtain 0.5g of yellow oil with a yield of 53.8%.

[0084] 1H NMR(600MHz,Chloroform-d)δ8.21(d,J=8.2Hz,1H),7.41–7.30(m,5H),7.20(dd, J=7.4Hz,2H),7.08–6.94(dd,J=7.3,7.3Hz,1H),4.27–3.94(m,4H),3.45(s,3H),3 .33(s,2H),3.19(t,J=8.4Hz,2H),2.85(d,J=11.7Hz,2H),2.54(t,J=11.5Hz,2H), 2.28(d,J=13.6Hz,2H),1.99–1.68(m,4H),0.96(t,J=7.4Hz,3H).(+)-ESI-MS:m / z 436.4 (calcd.436.3 for C 26 H 34 N3O3 + [M+H] + ).

[0085] Example 2

[0086] Synthesis of N-(1-(2-(6,7-dihydrothiophene[3,2-c]pyridin-5(4H)-yl)-2-oxoethyl)-4-(methoxymethyl)piperidin-4-yl)-N-phenylpropanamide (2)

[0087] The only difference from Example 1 is that 2,3-dihydro-1H-indole in step S1 is replaced by 4,5,6,7-tetrahydrothiophene[3,2-c]pyridine, and the other steps are basically the same and will not be repeated here.

[0088] 1 H NMR(600MHz,Chloroform-d)δ7.28–7.12(m,3H),6.93–6.71(m,4H),4.72–4.59(m,2H),3. 94(t,J=5.7Hz,1H),3.85(t,J=5.6Hz,1H),3.45(s,2H),3.42–3.23(m,6H),2.98(t,J=5.7 Hz,1H),2.90(t,J=5.7Hz,1H),2.88–2.66(m,4H),1.98(tt,J=14.2,3.4Hz,2H),1.86(tdd ,J=13.9,11.2,4.2Hz,2H),1.78(q,J=7.4Hz,2H),0.90(t,J=7.3Hz,3H).(+)-ESI-MS:m / z 456.4(calcd.456.2for C 25 H 34 N3O3S +[M+H] + ).

[0089] Example 3

[0090] Synthesis of N-phenyl-N-(1-(2-phenylacetyl)piperidin-4-yl)propionamide (3)

[0091] Reaction:

[0092]

[0093] Take 1.1g of N-phenyl-N-(piperidin-4-yl) propionamide (3b) and dissolve it in 25mL of dichloromethane. Cool it to 0-5℃ in an ice bath, add 2.3g of 2-phenylacetyl chloride (3a) dissolved in 10mL of dichloromethane dropwise, add 1.2g of triethylamine, and continue to react for 12h. After the reaction is completed, add 30mL of purified water, separate the dichloromethane layer with a separatory funnel, extract the water layer with dichloromethane twice (20mL*2), combine the dichloromethane layers, wash with saturated brine in turn, dry with anhydrous magnesium sulfate, and remove the solvent by distillation under reduced pressure to obtain a crude yellow oil. After silica gel column chromatography (200-300 mesh silica gel, dichloromethane: methanol = 30: 1), 1.4g of light yellow oil was obtained, with a yield of 47.4%.

[0094] 1 H NMR(500MHz,Chloroform-d)δ7.49–7.35(m,3H),7.24–7.16(m,3H),7.13(dd,J=7.7,1.8Hz,2H),7.03(d,J=6.6Hz,1H),6.89( d,J=7.2Hz,1H),4.82(tt,J=12.2,3.9Hz,1H),4.70(ddt,J=13.4,4.8,2.5Hz,1H),3.89–3.80(m,1H),3.70–3.60(m,2H),3.05( td,J=13.2,2.6Hz,1H),2.61(td,J=13.0,2.7Hz,1H),1.91(qd,J=7.5,2.2Hz,2H),1.79(ddd,J=12.6,4.2,2.3Hz,1H),1.68(dd d,J=12.4,4.2,2.3Hz,1H),1.16(qd,J=12.5,4.3Hz,1H),1.00(t,J=7.5Hz,3H),0.84(qd,J=12.5,4.4Hz,1H).(+)-ESI-MS:m / z 351.4(calcd.351.2for C 26 H 27 N2O2 + [M+H] +).

[0095] Example 4

[0096] Synthesis of N-(4-(methoxymethyl)-1-(2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (4) Reaction formula:

[0097]

[0098] S4. Synthesis of 4-(methoxymethyl)-N-phenyl-1-(2-(pyrrol-1-yl)ethyl)piperidin-4-amine (4b)

[0099] Take 0.4 g of 1-(2-chloroethyl)pyrrole hydrochloride (4a) and 0.4 g of 4-(methoxymethyl)-N-phenylpiperidin-4-amine (1b), dissolve them in 20 mL of acetonitrile, continue to add 0.6 g of triethylamine and 0.04 g of potassium iodide, heat to 60°C and reflux for 12 h. After the reaction is completed, remove the solvent by rotary evaporation to obtain 0.7 g of yellow oil, and obtain 0.5 g of light yellow oil by silica gel column chromatography (200-300 mesh silica gel, dichloromethane: methanol = 25: 1), with a yield of 83.0%.

[0100] S5. Synthesis of N-(4-(methoxymethyl)-1-(2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (4)

[0101] Take 0.5g of the reaction product of step S4 and 0.6g of propionyl chloride, dissolve them in 25mL of dichloromethane, react at room temperature for 1h, then add 0.6g of triethylamine and continue to react for 6h. After the reaction is completed, add 25mL of purified aqueous solution, stir for 5min, and separate the dichloromethane layer with a separatory funnel. Extract the water layer twice with dichloromethane and combine the dichloromethane layers, wash with saturated brine, dry with anhydrous sodium sulfate, and remove the solvent by rotary evaporation to obtain 0.6g of yellow oil. After silica gel column chromatography (200-300 mesh silica gel, dichloromethane: methanol = 25: 1), 0.5g of light yellow oil is obtained, with a yield of 83.6%.

[0102] 1H NMR(600MHz,DMSO-d6)δ7.42(dd,J=8.1,6.7Hz,2H),7.39–7.35(m,1H),7.35–7.30(m,2H ),3.99(s,2H),3.35(s,3H),3.29(t,J=6.4Hz,2H),3.19(t,J=6.7Hz,4H),2.94(t,J=6.4H z,2H),2.92–2.81(m,2H),2.61(t,J=10.7Hz,2H),2.13(d,J=14.0Hz,2H),1.95–1.84(m,4 H),1.79(t,J=10.2Hz,2H),1.73(q,J=7.4Hz,2H),0.81(t,J=7.4Hz,3H).(+)-ESI-MS:m / z 374.4(calcd.373.3for C 22 H 26 N3O2 + [M+H] + ).

[0103] Example 5

[0104] N-(4-(Methoxymethyl)-1-(2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (5)

[0105] The only difference from Example 4 is that 1-(2-chloroethyl)pyrrole hydrochloride (4a) in step S4 is replaced by 1-(2-chloroethyl)piperidine hydrochloride, and the other steps are basically the same and will not be repeated here.

[0106] 1 H NMR(600MHz, Deuterium Oxide)δ7.73–6.86(m,5H),4.08(s,2H),3.56–3.41(m,7H),3.36(s,3H),3.19(br.s,2H),2.91(t,J=12.4Hz,2H),2.43(br.s,2H),1.95– 1.76(m,5H),1.72(d,J=13.8Hz,2H),1.61(q,J=14.0,13.6Hz,2H),1.37(dd,J=13.3,12.8Hz,2H),0.79(t,J=7.4Hz,3H).(+)-ESI-MS:m / z 388.4(calcd.388.3for C 23 H 28 N3O2 + [M+H] + ).

[0107] Example 6

[0108] Synthesis of N-(4-(methoxymethyl)-1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (6)

[0109] The difference from Example 1 is that the 2,3-dihydro-1H-indole in step S1 is replaced by piperidine, and the other steps are basically the same and will not be repeated here.

[0110] 1 H NMR (600MHz, DMSO-d6) δ7.46 (dd, J=8.2, 6.7Hz, 2H), 7.43–7.39 (m, 1H), 7.37 (br.d, J=7 .6Hz,2H),4.18(s,2H),4.00(s,2H),3.45(t,J=5.6Hz,2H),3.36(s,3H),3.27(t,J=5.5H z,2H),3.24–3.13(m,2H),3.09(t,J=11.3Hz,2H),2.23(d,J=14.2Hz,2H),2.00(br.s,2 H), 1.75 (q, J = 7.3Hz, 2H), 1.59 (m, 2H), 1.52 (m, 2H), 1.44 (m, 2H), 0.82 (t, J = 7.4Hz, 3H).

[0111] (+)-ESI-MS:m / z 402.4(calcd.402.3for C 23 H 36 N3O3 + [M+H] + ).

[0112] Example 7

[0113] Synthesis of N-(4-(methoxymethyl)-1-(2-oxo-2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (7)

[0114] The difference from Example 1 is that 2,3-dihydro-1H-indole in step S1 is replaced by pyrrole, and the other steps are basically the same and will not be repeated here.

[0115] 1H NMR(600MHz,Chloroform-d)δ7.39–7.30(m,5H),4.07(s,2H),3.45(t,J=7.0Hz,2H),3.42(s,3H),3.41(t,J=6.8Hz,2H),3.21(s ,2H),2.84–2.73(m,2H),2.58–2.45(m,2H),2.24(dt,J=13.2,3.4Hz,2H),1.99–1.91(m,2H),1.84(m,6H),0.93(t,J=7.4Hz,3H).

[0116] (+)-ESI-MS:m / z 388.4(calcd.388.5for C 22 H 34 N3O3 + [M+H] + ).

[0117] Example 8

[0118] Synthesis of N-(1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (8)

[0119]

[0120] S6. Synthesis of 2-chloro-1-(piperidin-1-yl)ethan-1-one (8a)

[0121] Take 5.8g of 2-chloroacetyl chloride and dissolve it in 50mL of dichloromethane, cool it to 0-5℃ in an ice bath, add 3.3g of piperidine dissolved in 10mL of dichloromethane dropwise, add 9.2g of potassium carbonate, and continue to react for 11h. After the reaction is completed, add 30mL of purified water, separate the dichloromethane layer with a separatory funnel, extract the water layer with dichloromethane twice (20mL*2), combine the dichloromethane layers, wash them with saturated brine in turn, dry them with anhydrous magnesium sulfate, and remove the solvent by distillation under reduced pressure to obtain 5.4g of yellow oil with a yield of 85.3%.

[0122] S7. Synthesis of N-(1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (8)

[0123] Take 1.3 g of the reaction product of step S6 and 1.4 g of N-phenyl-N-(piperidin-4-yl) propionamide (3b), dissolve in 50 mL of acetonitrile, continue to add 1.6 g of triethylamine and 0.2 g of potassium iodide, heat to 60 ° C and stir to react for 12 hours. After the reaction is completed, the solvent is removed by rotary evaporation to obtain 1.3 g of yellow oil, which is subjected to silica gel column chromatography (200-300 mesh silica gel, dichloromethane: methanol = 25: 1) to obtain 1.0 g of light yellow solid, with a yield of 47.8%.

[0124] 1 H NMR(600MHz,Chloroform-d)δ7.49–7.34(m,3H),7.14–6.97(m,2H),4.65(tt ,J=12.2,3.9Hz,1H),3.49(t,J=5.6Hz,2H),3.37(t,J=5.5Hz,2H),3.20(s,2H ),3.04–2.90(m,2H),2.44–2.22(m,2H),1.93(q,J=7.5Hz,2H),1.79(ddd,J= 12.0, 4.5, 2.4Hz, 2H), 1.66–1.55 (m, 2H), 1.50 (m, 6H), 1.01 (t, J = 7.5Hz, 3H).

[0125] (+)-ESI-MS:m / z 358.2(calcd.358.5for C 21 H 32 N3O2 + [M+H] + ).

[0126] Example 9

[0127] Synthesis of N-(1-(2-oxo-2-(pyrrol-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide (9)

[0128] The difference from Example 8 is that the piperidine in step S6 is replaced by pyrrole, and the other steps are basically the same and will not be repeated here.

[0129] 1H NMR (600MHz, Chloroform-d) δ7.32 (m, 3H), 7.03–6.93 (m, 2H), 4.59 (tt, J = 12. 2,3.9Hz,1H),3.36(t,J=7.0Hz,2H),3.31(t,J=6.8Hz,2H),3.06(s,2H),2.96( dt,J=10.8,2.2Hz,2H),2.30(t,J=11.7Hz,2H),1.90–1.80(m,4H),1.77–1.72( m,2H),1.73–1.67(m,2H),1.49(td,J=12.3,3.9Hz,2H),0.93(t,J=7.5Hz,3H).

[0130] (+)-ESI-MS:m / z 344.2(calcd.344.5for C 20 H 30 N3O2 + [M+H] + ).

[0131] Table 1 Numbers and structural formulas of compounds prepared in Examples 1-9

[0132]

[0133]

[0134]

[0135]

[0136] B. Pharmacological Examples

[0137] Example 10

[0138] Preparation of μ receptor membrane and determination of ligand affinity

[0139] Preparation of μ receptor membrane

[0140] CHO-μ was taken out of the -80℃ freezer and thawed naturally. It was centrifuged at 2000g for 10 min, and buffer A (50mM Tris-HCl, 10mM MgCl2, 0.1mM EDTA, pH 7.4) or buffer B (50mM ADA, 10mM MgCl2, 0.1mM EDTA, pH 6.4) was added to the precipitate. The precipitate was mixed with a vortex mixer and centrifuged at 50000g, 4℃ for 25 min. The supernatant was discarded, the precipitate was taken, and the centrifugation was repeated once. After the centrifugation was completed, the supernatant was discarded and the precipitate was stored at -80℃ for later use.

[0141] μ opioid receptor competition binding assay

[0142] Step 1: First, prepare the prepared membrane into a 10 mg / mL membrane suspension using a standard binding buffer for later use.

[0143] Step 2: Add 100ul of membrane preparation to each reaction tube.

[0144] Step 3: Add 100 μl of standard binding buffer to the total binding tube (TB) and 10 μM DAMGO (final concentration 1.0×10 -5 M) 100 μl, and 100 μl of the test compound was added to each test compound specific binding tube (CB).

[0145] Step 4: Add 3 nM of radioligand to each reaction tube 3 H]-DAMGO 10 μl.

[0146] Step 5: Incubate each reaction tube at 25°C for 90 min. After the reaction is completed, the bound ligand is quickly filtered under reduced pressure. The Whatman test paper GF / B is saturated with 0.5% PEI solution 1 hour in advance, and washed thoroughly with ice-cold Tris buffer. After filtration, the filter membrane is dried at 60°C, and 40μl scintillation fluid is added after the base membrane is attached. The upper membrane is sealed and allowed to stand.

[0147] Step 6: Place the scintillation vial into a liquid scintillation counter for counting.

[0148] Data processing and statistical analysis

[0149]

[0150] Where, TB: total binding constant

[0151] NB: nonspecific binding constant

[0152] CB: compound-specific binding constant.

[0153] Table 2 In vitro experimental results of compounds on μ receptors under different pH conditions

[0154]

[0155] Embodiment 11

[0156] Acetic acid writhing test in mice

[0157] ICR mice, female, 22–30 g, were randomly divided into negative control group, model group, positive drug group (pregabalin and fentanyl) and compound dose groups, 8 mice in each group. The negative control group and model group were subcutaneously administered with the corresponding solvent saline, the positive drug group was subcutaneously administered with the corresponding positive drug, and the compound dose groups were subcutaneously administered with the corresponding dose of compound, and the administration volume was 10 mL / kg. 5 minutes after subcutaneous administration, 1% acetic acid was intraperitoneally administered to the mice, and the number of twisting of the mice within 30 minutes was recorded. The compound test results were compared with the model test results, and the twisting inhibition rate was used as an objective criterion for judging whether there was analgesia. The results are shown in Table 3 below.

[0158] Table 3 In vivo experimental results of compound 6

[0159]

[0160] The results of the acetic acid writhing test on mice of the preferred compound 6 are as follows Figure 2 As shown, the number of twisting of saline samples, samples of the present invention with different application amounts, and samples of pregabalin with different application amounts were tested respectively. It can be seen that when the application amount of compound 6 of the present invention is 10 mg / kg, the number of twisting is less than 10 times, which is much lower than the number of twisting of pregabalin 50 mg / kg, which shows that the analgesic effect of the present invention is significant.

[0161] Example 12

[0162] Formalin-induced pain model experiment in rats

[0163] SD rats, male, 200–260 g, were randomly divided into negative control group, model group, positive drug group (pregabalin and fentanyl) and compound dose groups, 8 rats in each group. The negative control group and model group were subcutaneously administered with the corresponding solvent saline, the positive drug group was subcutaneously administered with the corresponding positive drug, and the compound dose groups were subcutaneously administered with the corresponding dose of compound, with the administration volume of 5 mL / kg. 5 min after subcutaneous administration, 75 ul of 5% formalin was injected into the sole of the left hind foot of the rat to establish the model, and the formation of a skin mound was the standard for successful modeling. The software automatically recorded the number of foot lifts in the 1-min time period between 0-60 min after modeling, and then analyzed and calculated the total number of foot lifts of rats in phase I (1-10 min) and phase II (10-60 min) according to the results of the software. The results of compound phase II were compared with those of model phase II, and the foot lift inhibition rate was used as an objective standard for judging whether there was analgesia.

[0164] The experimental results of the rat formalin-induced pain model of the preferred compound 6 are as follows Figure 3 shown.

[0165] Example 13

[0166] Naloxone-induced withdrawal experiment in mice

[0167] The physical dependence potential of the selected compounds was evaluated using the naloxone withdrawal test in mice. The compounds were tested by escalating doses (1-, 5-, 10-, 15-, 20-, 25-, and 30-fold ED 50 The mice were subcutaneously injected with drugs at 9:00 a.m. and 8:00 p.m. every day. Two hours after the morning administration on the seventh day, 2 mg / kg of naloxone was subcutaneously injected and transferred to a plastic cylinder (20 cm in diameter and 40 cm in height). The jumping behavior (typical characteristic behavior of withdrawal reaction) of each mouse was observed within 30 minutes. The difference between the solvent group and the drug group was compared to evaluate the physical dependence of each compound. The results of the naloxone-induced withdrawal experiment on mice with compound 6 were shown as follows: Figure 4 shown.

[0168] Among them, the positive drug Fentanyl group had a statistically significant difference with the solvent group, while the average number of jumps in the compound 6 group had no statistically significant difference with the solvent group, indicating that compound 6 had almost no physical dependence.

[0169] The results showed that: In vitro experiments showed that compound 6 had moderate MOR affinity, and the activity of the compound under pathological conditions (pH 6.4) was 6.6 times that under physiological conditions (pH 7.4), which has the advantage of targeting pathological environments. In vivo animal experiments showed that compound 6 had a strong analgesic effect in the acetic acid writhing model and formalin model, and its ED 50 The values ​​were 1.5mg / kg and 12.9mg / kg, respectively. In the formalin model, compound 6 had a better analgesic effect on phase II (inflammatory, persistent) pain, which was significantly different from traditional opioids and showed its uniqueness. In the side effect evaluation experiment, compound 6 had a lower physical dependence side effect than fentanyl at the same analgesic dose.

[0170] C. Composition Examples

[0171] Embodiment 14

[0172] tablet

[0173]

[0174]

[0175] The raw and auxiliary materials are sieved through an 80-mesh sieve for later use. The prescribed amount of active ingredients, microcrystalline cellulose, lactose, and povidone K30 are weighed and added to a high-speed mixer. The mixture is stirred at a low speed and mixed evenly. An appropriate amount of purified water is added. The mixture is stirred at a low speed and granulated at a high speed. The wet granules are dried at 65°C for 2.5 h, sieved through a 24-mesh sieve, and the prescribed amount of sodium carboxymethyl starch, silicon dioxide, and magnesium stearate are added. The mixture is mixed and the tablets are compressed on a rotary tablet press.

[0176] Embodiment 15

[0177] Injection

[0178] Components Dosage Active ingredient (compound of the present invention) 5mg Sodium chloride 45mg hydrochloric acid Moderate Water for injection 5g

[0179] According to the above prescription, the production process is sequentially carried out through (1) bottle sorting, bottle washing and sterilization steps; (2) preparation step; (3) filtration step; (4) filling step; (5) sterilization and leak detection step; (6) light inspection step; and (7) packaging step to obtain an injection solution containing the active ingredient of the compound of the present invention.

[0180] In summary, the compound of general formula I provided by the present invention has a high affinity for μ receptors, and the affinity for μ receptors under different pH conditions is pH-sensitive. At the same time, the results of animal experiments also show that the compound of the present invention can not only significantly improve the phase I and phase II pain induced by formalin, but also show good analgesic activity in the acetic acid writhing experiment. Since these in vitro action targets and in vivo pharmacological models are closely related to pain, the compound provided by the present invention has the potential to prepare drugs for treating pain-related diseases.

[0181] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.

Claims

1. A pH-sensitive 4-amidopiperidine derivative, characterized in that: The compound represented by formula I or its pharmaceutically acceptable salt: The compound represented by formula I or a pharmaceutically acceptable salt thereof is: N-(4-(methoxymethyl)-1-(2-oxo-2-(piperidin-1-yl)ethyl)piperidin-4-yl)-N-phenylpropanamide.

2. The pH-sensitive 4-amidopiperidine derivative according to claim 1, characterized in that: The pharmaceutically acceptable salt is a salt containing a pharmaceutically acceptable anion; the anion salt is hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, oxalate, acetate, propionate, lactate, citrate, tartrate, maleate, fumarate, methanesulfonate, ethanesulfonate, propanesulfonate, gluconate, glucarate, benzoate, p-toluate, benzenesulfonate or p-toluenesulfonate.

3. A pharmaceutical composition, characterized in that The invention comprises the pH-sensitive 4-amide piperidine derivative according to any one of claims 1 to 2, and one or more of a pharmaceutically acceptable carrier, an excipient, a binder, a disintegrant, a lubricant or a sweetener.

4. Use of a pH-sensitive 4-amide piperidine derivative according to any one of claims 1 to 2 in the preparation of a drug for preventing or treating pain.

5. The use according to claim 4, characterized in that: The pain is moderate to severe pain, chronic pain, neuralgia, inflammatory pain, nociceptive pain, cancer pain, acute pain, hyperalgesia, and visceral pain.

Citation Information

Patent Citations

  • Fentanyl analogue and application thereof

    CN108503579A